Infant and child formula food for improving and / or improving individual social behaviors and preparation method thereof

Abstract

The invention provides infant and child formula food for improving and / or improving individual social behaviors and a preparation method thereof. The invention firstly provides the infant formula food, the infant formula food is infant formula food, infant formula food or child formula food, the infant formula food comprises DHA, ARA and breast milk oligosaccharide 6-SL and / or LNnT, and the mass ratio of the DHA to the ARA to the breast milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (10-400). The formulae of the present invention contribute to enhancing and / or improving the social behavior of an individual.

Description

Technical Field

[0001] The present invention belongs to the technical field of infant and children's formula food, and specifically relates to an infant and children's formula food that helps to enhance and / or improve individual social behavior, and a preparation method and application thereof. Background Art

[0002] In the field of infant and children's formula, a core technical issue is how to design and prepare formula foods that can simulate the nutritional components and functions of breast milk to promote the healthy growth of infants and young children. Breast milk not only provides essential nutrients, but also contains a variety of bioactive ingredients that have an important impact on the neurodevelopment and behavioral performance of infants and young children. However, when breast milk is lacking or insufficient, existing infant and children's formula foods often find it difficult to fully replicate these complex components and functions in breast milk, especially in promoting the development of social behavior.

[0003] Social behavior refers to an individual's ability to interact with people around him or her and to take care of himself or herself. It is one of the attributes for assessing the developmental behavior level of children aged 0 to 6 years old (under 7 years old).

[0004] After searching, there are few reports in the prior art on whether diet affects individual social behavior and what kind of impact it has on individual social behavior. Summary of the invention

[0005] An object of the present invention is to provide an infant and children's formula that helps to greatly enhance and / or improve the social behavior of an individual.

[0006] Another object of the present invention is to provide related applications of the infant and children's formula food.

[0007] The present invention has found that polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and arachidonic acid (ARA), human milk oligosaccharides (such as 6-SL, LNnT, etc.) and their compositions (i.e., compositions comprising DHA, ARA and human milk oligosaccharides) can affect the social behavior of an individual. In particular, when DHA, ARA and human milk oligosaccharides (especially 6-SL and / or LNnT) are combined in a certain proportion, they have a synergistic effect on enhancing and / or improving the social behavior of an individual.

[0008] On the one hand, the present invention provides a pediatric formula food, which is an infant formula food, a toddler formula food or a children's formula food, wherein the pediatric formula food has a total protein content of 10-30 g / 100 g, a fat content of 10-35 g / 100 g, a dietary fiber content of 0-6.5 g / 100 g, and a carbohydrate content of 45-60 g / 100 g; and the pediatric formula food contains DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, wherein the mass ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is (70-210):(60-420):(10-400).

[0009] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA to ARA is 0.2-5:1.

[0010] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA to ARA is 0.3-3:1.

[0011] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2.5:1.

[0012] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-2:1.

[0013] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA to ARA is preferably 0.5-1.5:1, for example 0.5:1, 0.6:1, 0.67:1, 0.8:1, 1:1, 1.1:1, 1.2:1, 1.3:1 or 1.4:1.

[0014] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (40-400).

[0015] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210): (60-420): (80-400).

[0016] According to a specific embodiment of the present invention, the pediatric formula food of the present invention comprises DHA, ARA and 6-SL.

[0017] According to some specific embodiments of the present invention, the pediatric formula food of the present invention comprises DHA, ARA and LNnT.

[0018] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw material for providing the DHA can be a commercially available DHA raw material with higher purity, or it can be a DHA oil and / or powder derived from one or a combination of two or more of algae, tuna oil, fish oil, milk-derived DHA from feed nutritional regulation and biotransformation, egg yolk extract and krill oil; wherein the algae can be one or a combination of two or more of Schizochytrium, Okenichytrium and Crypthecodinium. Unless otherwise specified, the ratio of the DHA to other functional components in the pediatric formula food of the present invention is based on the content of DHA in the raw material.

[0019] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw material for providing the ARA can be a commercially available ARA raw material with higher purity, or can be one or more raw materials derived from algae and other oils containing ARA. Unless otherwise specified, the ratio of the ARA to other functional components in the pediatric formula food of the present invention is based on the content of ARA in the raw material.

[0020] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw material for providing the human milk oligosaccharide 6-SL and / or LNnT can be a commercially available human milk oligosaccharide raw material with higher purity. Unless otherwise specified, the ratio of the human milk oligosaccharide 6-SL and / or LNnT to other functional components in the special medical purpose formula food of the present invention is based on the content of human milk oligosaccharide 6-SL and / or LNnT in the raw material. When the human milk oligosaccharide in the special medical purpose formula food of the present invention is 6-SL and LNnT, its ratio with other functional components is based on the total content of 6-SL and LNnT in the raw material, wherein 6-SL and LNnT can be in any ratio.

[0021] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the food is 10-400 mg / 100 g of food dry matter.

[0022] According to a specific embodiment of the present invention, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the pediatric formula food of the present invention is 80-300 mg / 100 g of food dry matter.

[0023] In some specific embodiments of the present invention, the amount of human milk oligosaccharide 6-SL contained in the pediatric formula food of the present invention is 80-300 mg / 100 g of food dry matter.

[0024] In some specific embodiments of the present invention, the amount of human milk oligosaccharide LNnT contained in the pediatric formula food of the present invention is 80-200 mg / 100 g of food dry matter.

[0025] According to a specific embodiment of the present invention, the content of DHA and ARA in the infant formula food of the present invention can be determined according to the ratio with the human milk oligosaccharide 6-SL and / or LNnT.

[0026] According to a specific embodiment of the present invention, the pediatric formula food of the present invention preferably contains a total amount of DHA and ARA of 130-630 mg / 100 g of food dry matter.

[0027] According to a specific embodiment of the present invention, the pediatric formula food of the present invention preferably contains 2700-4500 mg / 100 g of linoleic acid and 270-450 mg / 100 g of α-linolenic acid.

[0028] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the dietary fiber includes one or more of galacto-oligosaccharides and fructo-oligosaccharides.

[0029] In addition, the pediatric formula of the present invention may be in the form of a solid composition or a liquid composition.

[0030] In a specific embodiment, the pediatric formula food of the present invention is a dairy product, which can be a solid dairy product or a liquid dairy product. Specifically, it can be in the form of cheese, liquid dairy product, milk flakes or milk powder.

[0031] In a more specific embodiment, the pediatric formula food of the present invention is milk powder, and is prepared by adding DHA, ARA and human milk oligosaccharide 6-SL and / or LNnT to a basic formula powder. And, more specifically, the basic formula powder is an infant formula powder.

[0032] It is understandable that for different types of pediatric formula foods, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0033] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw materials providing total protein include: raw milk (cow / sheep), whole milk powder (cow / sheep), skimmed milk powder (cow / sheep), whey protein powder (cow / sheep), desalted whey powder (cow / sheep), β-casein, etc. One or more.

[0034] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw materials providing fat include vegetable oil or OPO structured fat in addition to the basic raw materials containing milk fat.

[0035] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw materials providing carbohydrates include: 0 to 350 parts of lactose, and / or the above-mentioned protein raw materials containing lactose.

[0036] According to a specific embodiment of the present invention, in the children's formula food of the present invention, a part of the carbohydrates can come from basic raw materials containing lactose such as milk, whole milk powder and / or skim milk powder, etc., and lactose raw materials can be additionally added to provide carbohydrates. That is, in the children's formula food of the present invention, the raw materials for providing carbohydrates include raw material lactose in addition to the basic raw materials containing lactose. Preferably, based on 1000 parts by weight of the children's formula food, its raw materials include: 50 to 225 parts by weight of lactose. The specific amount of lactose added can be adjusted within the range so that the carbohydrate content of the children's formula food of the present invention is 45 to 60g / 100g.

[0037] According to a specific embodiment of the present invention, the raw materials of the pediatric formula food of the present invention may also include one or a combination of two or more of appropriate nucleotides, lactoferrin, etc.

[0038] According to a specific embodiment of the present invention, the raw materials of the pediatric formula food of the present invention may also include compound nutrients including calcium powder, vitamins and minerals. The compound nutrients are a combination of nutrients that meet national standards, and different addition amounts are used according to different formulas. Preferably, based on 1000 parts by weight of pediatric formula food, its raw materials include: 7 to 25 parts by weight of compound nutrients including calcium powder, vitamins and minerals. More preferably, the compound nutrients are added in the form of at least a compound vitamin package, calcium powder, and a mineral nutrient package. Specifically, the compound nutrients are preferably added in the form of the following nutrient packages:

[0039] 1) Compound vitamin nutrient pack, the content of each component in each gram of compound vitamin nutrient pack is as follows:

[0040] Taurine: 0-340 mg

[0041] Vitamin A: 1200~7000μgRE

[0042] Vitamin D: 20-112 μg

[0043] Vitamin B 1 :1500~14000μg

[0044] Vitamin B 2 :3500~14000μg

[0045] Vitamin B 6 :1000~7000μg

[0046] Vitamin B 12:8~30μg

[0047] Vitamin K 1 :200~750μg

[0048] Vitamin C: 0-800 mg

[0049] Vitamin E: 10-70 mg α-TE

[0050] Nicotinamide: 10,000-47,000 μg

[0051] Folic acid: 420-3000 μg

[0052] Biotin: 38-245 μg

[0053] Pantothenic acid: 6000-60000 μg

[0054] Inositol: 0-250 mg

[0055] L-carnitine: 0-150 mg 2) Mineral 2 nutritional package, the content of each component in each gram of mineral 2 nutritional package is as follows: Calcium: 120-6000 mg

[0056] Phosphorus: 0-150 mg 3) Mineral nutrition pack, the content of each component in each gram of mineral nutrition pack is as follows: Iron: 25-135 mg

[0057] Zinc: 23-175 mg

[0058] Copper: 2600-12000 μg

[0059] Iodine: 0-995 μg

[0060] Selenium: 0-200 μg

[0061] Manganese: 0~15000μg

[0062] 4) Compound magnesium chloride nutrient pack, each gram of compound magnesium chloride nutrient pack contains:

[0063] Magnesium: 80-2800 mg

[0064] 5) Compound potassium chloride nutrient pack, each gram of compound potassium chloride nutrient pack contains:

[0065] Potassium: 0-580 mg;

[0066] 6) Choline chloride nutrient pack, each gram of choline chloride nutrient pack contains:

[0067] Choline: 300-1500 mg;

[0068] Preferably, based on 1000 parts by weight of the pediatric formula food, the added amount of the compound vitamin nutrient package is 2 to 4 parts by weight, the added amount of the mineral 2 nutrient package is 2 to 18 parts by weight, the added amount of the mineral 1 nutrient package is 0.5 to 3 parts by weight, the added amount of the compound magnesium chloride nutrient package is 0 to 2 parts by weight, the added amount of the compound potassium chloride nutrient package is 0 to 4.5 parts by weight, and the added amount of choline chloride nutrient is 0 to 2 parts by weight, and the base material of each nutrient package is preferably lactose or sodium L-ascorbate.

[0069] According to a specific embodiment of the present invention, the raw material of the pediatric formula food of the present invention may further include probiotics, preferably, the probiotics are bifidobacteria. More preferably, based on 1000 parts by weight of the pediatric formula food, the amount of bifidobacteria added is 0 to 2.5 parts by weight; more preferably, 0.18 to 0.5 parts by weight. More preferably, each part by weight of the bifidobacterium powder contains 3×10 10 CFU or above.

[0070] According to a preferred embodiment of the present invention, the infant formula food of the present invention comprises:

[0071]

[0072] 7 to 25 parts by weight of a compound nutrient comprising calcium powder, vitamins and minerals;

[0073]

[0074] It is understood that the specific amount of each raw material in the pediatric formula food of the present invention should be adjusted and determined under the premise of meeting the requirements of the formula food product index. In the pediatric formula food of the present invention, the product performance indicators not described or listed in detail should be implemented in accordance with the national standards for infant or children's formula food and relevant standards and regulations.

[0075] In the pediatric formula food of the present invention, each raw material can be commercially available, and the selection of each raw material should comply with the requirements of relevant standards, wherein the composition should also meet the requirements of the present invention. In addition, the compounded nutrients can also be compounded by themselves. The present invention only uses "compounding" for the convenience of expression, and does not mean that the components in the compound must be mixed together before use. Each raw material should be added and used under the premise of meeting relevant laws and regulations.

[0076] On the other hand, the present invention also provides a method for preparing the pediatric formula food, the method comprising:

[0077] Preparing raw materials for infant formula food, wherein the content of DHA, ARA and human milk oligosaccharide 6-SL and / or LNnT in the raw materials is adjusted;

[0078] The raw materials are batched, homogenized, concentrated and sterilized, spray-dried and dry-mixed to prepare the pediatric formula food.

[0079] In some specific embodiments of the present invention, the preparation method comprises:

[0080] 1) Milk coarse filtration: After the milk is coarsely filtered and degassed in the balance cylinder, it is preheated by a plate heat exchanger and then separated from impurities by a separator.

[0081] 2) Milk homogenization and sterilization: After removing impurities, part of the raw milk enters the homogenizer for homogenization, and the other part is not homogenized. After homogenization, the two are mixed and enter the sterilization system for sterilization.

[0082] 3) Powder addition: Various powder raw materials are measured according to the formula and added into the powder mixing tank through the air delivery system for storage.

[0083] 4) Vacuum powder suction: Various powder raw materials in the powder mixing tank are sucked into the vacuum mixing tank through the vacuum system.

[0084] 5) Melting and oil preparation: Put the grease specified in the formula into the carburettor room according to the formula requirements. The temperature in the carburettor room should be maintained at 50-90°C. After the oil is dissolved, it is pumped into the mixed oil storage tank through the oil pump and flow meter according to the formula ratio requirements.

[0085] 6) Storage of mixed oil: The mixed oil is stored in an oil storage tank at a temperature of 40-50°C and the storage time is less than 12 hours to prevent fat oxidation.

[0086] 7) Weighing: Pump the mixed oil into the mixing tank through the oil pump according to the formula requirements.

[0087] 8) Dissolved and added nutrients: Calcium powder, minerals, vitamins, etc. are added separately with 100-200 kg of pure water. After dissolving them separately, they are pumped into the wet mixing tank. After each one is added, rinse the addition tank and pipeline with 100 kg of pure water.

[0088] 9) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials.

[0089] 10) Homogenization: The mixed liquid is homogenized by a homogenizer. The first-stage homogenization pressure is 105±5 bar and the second-stage homogenization pressure is 32±3 bar. The fat globules are mechanically treated and dispersed into uniform fat globules.

[0090] 11) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: it is cooled to below 20°C and temporarily stored in the pre-storage tank. It enters the next process within 6 hours, and the agitator is turned on according to the set requirements.

[0091] 12) Concentration and sterilization: Double-effect concentration is used during production, the sterilization temperature is ≥83°C, and the sterilization time is 25 seconds. The discharge concentration is 48% to 52% dry matter.

[0092] 13) Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank. It is preheated to 60-70℃ by the scraper preheater. After preheating, the material is filtered through a filter with a pore size of 1mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Inlet air temperature: 165-180℃, exhaust air temperature 75-90℃, high-pressure pump pressure 160-210bar, tower negative pressure -4--2mbar.

[0093] 14) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary) and then cooled to 25-30°C in a fluidized bed (secondary). At the same time, the lecithin is mixed with the carrier and heated to 60-65°C. Under the action of compressed air, it is evenly dispersed on the surface of the powder, so that the powder particles agglomerate to increase its particle size and solubility.

[0094] 15) Packaging: The flour-making workshop staff weighs DHA, ARA lactoferrin and bifidobacteria and packs them in bags according to the formula requirements.

[0095] 16) Dry mixing: Mix the weighed DHA, ARA, lactoferrin and milk powder in a dry mixer.

[0096] 17) Powder screening: Use a vibrating screen to make the particle size of the milk powder uniform and discard the powder residue.

[0097] 18) Powder output: Collect the powder in a sterilized powder box and transport it from the powder output room to the powder loading room.

[0098] 19) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0099] 20) Packaging: 800g automatic packaging machine nitrogen filling packaging. The oxygen content during nitrogen filling is less than 1%. 900g iron cans automatically filled with nitrogen packaging oxygen content less than 5%.

[0100] 21) Packing: Put the packaged sachets into cartons and add the powder spoon, then seal with a carton sealing machine.

[0101] 22) Finished product inspection: Sampling inspection is carried out on the packaged products according to the inspection plan.

[0102] 23) Storage: Products that have passed the inspection shall be stored in warehouses at room temperature with humidity ≤ 65%.

[0103] On the other hand, the present invention also provides the use of the pediatric formula food in preparing a product that helps to enhance and / or improve the social behavior of an individual. The product can be the pediatric formula food of any of the aforementioned schemes of the present invention, or can be further prepared from other products based on the pediatric formula food of the present invention.

[0104] According to some specific embodiments of the present invention, the functional components in the pediatric formula food are composed of DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, and the proportions of the components can be any of the above proportions of the present invention. The efficacy refers to enhancing and / or improving the social behavior of an individual.

[0105] According to a specific embodiment of the present invention, in the present invention, the enhancing and / or improving the social behavior of an individual includes: enhancing the social willingness and / or social ability of an individual.

[0106] According to a specific embodiment of the present invention, in the present invention, the social ability includes social adaptability (the ability of an individual to respond to and adapt to the social environment and / or social needs around him / her).

[0107] According to a specific embodiment of the present invention, the pediatric formula food of the present invention is used in the preparation of a product for improving and / or improving the social behavior of an individual, wherein the individual is an infant, a toddler or a child. The infant and children's formula food of the present invention can improve the low social behavior of an individual.

[0108] In the present invention, unless otherwise specified, the infant refers to an infant of 0-12 months, the toddler refers to an infant of 1-3 years old, and the child refers to a minor, particularly a child of 0 to 6 years old (under 7 years old).

[0109] The pediatric formula food provided by the present invention comprises polyunsaturated fatty acids DHA, ARA and phospholipids, which are helpful to enhance and / or improve the social behavior of an individual, and these functional components have a certain synergistic effect in enhancing and / or improving the social behavior of an individual. BRIEF DESCRIPTION OF THE DRAWINGS

[0110] Figure 1 The results of the approach cumulative time test for the 1:1 DHA and ARA combination experimental group are shown.

[0111] Figure 2 The detection results show the approaching frequency of the experimental group of 1:1 DHA and ARA combination.

[0112] Figure 3 The test results of the cumulative body contact time of the 1:1 DHA and ARA combination experimental group are shown.

[0113] Figure 4The results of the body contact frequency test for the 1:1 DHA and ARA combination experimental group are shown.

[0114] Figure 5 The results of the relative movement accumulation time test of the 1:1 DHA and ARA combination experimental group are shown.

[0115] Figure 6 The results of the relative movement frequency test of the 1:1 DHA and ARA combination experimental group are shown.

[0116] Figure 7 The test results of the approach cumulative time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0117] Figure 8 The results of the detection of the approaching frequencies of the experimental groups of the compositions of DHA and ARA at different ratios are shown.

[0118] Fig. 9 The test results of the cumulative body contact time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0119] Fig.10 The results of the body contact frequency test of the experimental groups of different ratios of DHA and ARA compositions are shown.

[0120] Fig.11 The test results of the relative movement cumulative time of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0121] Fig.12 The results of the relative movement frequency test of the experimental groups of DHA and ARA compositions with different ratios are shown.

[0122] Fig.13 The results of the test showing the cumulative time of convergence for different HMO experimental groups.

[0123] Fig.14 Results showing the detection of convergence frequencies for different HMO experimental groups.

[0124] Fig.15 Results showing the cumulative duration of physical contact for the different HMO experimental groups.

[0125] Fig.16 Results showing the frequency of physical contact for different HMO experimental groups.

[0126] Fig.17 The results of the relative movement accumulation time test of different HMO experimental groups are shown.

[0127] Fig.18 Results showing the relative movement frequencies of different HMO experimental groups.

[0128] Fig.19 The test results showing the approach cumulative time for the DHA+ARA+HMO experimental group.

[0129] Fig. 20 The results of the detection of the approaching frequency of the DHA+ARA+HMO experimental group are shown.

[0130] Fig.21 The test results showing the cumulative time of body contact for the DHA+ARA+HMO experimental group.

[0131] Fig. 22 The test results showing the frequency of physical contact for the DHA+ARA+HMO experimental group.

[0132] Fig.23 The test results of the relative movement cumulative time of the DHA+ARA+HMO experimental group are displayed.

[0133] Fig.24 The results of the relative movement frequency test of the DHA+ARA+HMO experimental group are shown. DETAILED DESCRIPTION

[0134] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0135] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0136] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0137] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0138] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0139] In each embodiment and experiment, the DHA, ARA and HMO used are all commercially available food grade raw materials. Unless otherwise specified, the DHA, ARA and HMO mentioned in the present invention are all calculated based on the effective content of the functional components DHA, ARA and HMO in the raw materials.

[0140] Example 1

[0141] The present embodiment provides a powdered formula food for infants and children, wherein the total protein content of the powdered formula food is 10.5 g / 100 g powder, the fat content is 27 g / 100 g powder, the carbohydrate content is 54.2 g / 100 g powder, the DHA content is 150 mg / 100 g powder, the ARA content is 200 mg / 100 g powder, and the LNnt content is 375 mg / 100 g powder, and the ratio of DHA:ARA:LNnt is 150:200:375.

[0142] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0143] 800 parts of raw cow milk, 300 parts of desalted whey powder (D90), 220 parts of edible vegetable blending oil, 190 parts of lactose, 35 parts of galacto-oligosaccharide, 27 parts of α-lactalbumin powder, 22 parts of casein, 8 parts of oligofructose, 5 parts of whey protein powder (rich in milk fat globule membrane), 4 parts of phospholipids, 23.7 parts of compound nutrients, 24 parts of compound nutrients, wherein the compound nutrients include about 4 parts of compound vitamin nutrition package, about 2 parts of choline chloride nutrition package, about 12 parts of mineral 2 nutrition package, about 1 part of mineral 1 nutrition package, about 2 parts of magnesium chloride nutrition package and about 3 parts of potassium chloride nutrition package, the base material of each nutrition package is lactose, 15 parts of 2'-fucosyllactose (2'-FL), 4 parts of lactose-N-neotetraose (LNnT), DHA 16 parts, ARA 22 parts, lactoferrin about 7 parts, bifidobacterium 0.4 parts, nucleotides about 0.7 parts.

[0144] The specific preparation process of the infant and children's formula milk powder of this embodiment is as follows:

[0145] 1) Milk coarse filtration: After the milk is coarsely filtered and degassed in the balance cylinder, it is preheated by a plate heat exchanger and then separated from impurities by a separator.

[0146] 2) Milk homogenization and sterilization: After removing impurities, part of the raw milk enters the homogenizer for homogenization, and the other part is not homogenized. After homogenization, the two parts are mixed and enter the sterilization system for sterilization.

[0147] 3) Powder addition: various powder raw materials are added to the powder mixing tank through the air delivery system after being measured according to the formula, and then sucked into the vacuum mixing tank through the vacuum system;

[0148] 4) Melting and preparing oil: put the oil specified in the formula into the oiling room according to the formula requirements. The temperature in the oiling room is maintained at 50-90°C. After the oil is dissolved, pump it into the mixed oil storage tank, and then pump the mixed oil into the mixing tank through the oil pump according to the formula requirements;

[0149] 5) Dissolving and adding nutrients: Dissolve calcium powder, vitamins, minerals and other nutrient packages separately with purified water, and add them to the mixing tank in sequence to obtain a mixed liquid.

[0150] 6) Filtration: The mixed liquid is filtered through a filter to remove physical impurities that may be introduced into the raw materials.

[0151] 7) Homogenization: The mixed liquid is homogenized by a homogenizer to mechanically treat the fat globules and disperse them into uniform fat globules.

[0152] 8) Cooling and storage: The homogenized liquid enters the plate heat exchanger for cooling: it is cooled to below 20°C and temporarily stored in the pre-storage tank. It enters the next process within 6 hours, and the agitator is turned on according to the set requirements.

[0153] 9) Concentration and sterilization: Double-effect concentration is used during production, the sterilization temperature is ≥83°C, and the sterilization time is 25 seconds. The discharge concentration is 50% dry matter.

[0154] 10) Concentrated milk storage, preheating filtration, spray drying: The concentrated milk is temporarily stored in the concentrated milk balance tank. It is preheated to 60°C by a scraper preheater. After preheating, the material is filtered through a filter with a pore size of 1mm, and then pumped into the drying tower for spray drying by a high-pressure pump. The fine powder is agglomerated at the top of the tower or in the fluidized bed as required. Inlet air temperature: 180°C, exhaust air temperature 86°C, high-pressure pump pressure 200bar, tower negative pressure about -4mba.

[0155] 11) Fluidized bed drying and cooling: The powder coming out of the drying tower is dried again in a fluidized bed (primary stage) and then cooled to 30°C in a fluidized bed (secondary stage) to obtain the main ingredient of milk powder.

[0156] 12) Packaging: According to the formula requirements, weigh the DHA, ARA or bifidobacteria and seal the bags for packaging.

[0157] 13) Dry mixing: Mix the weighed DHA, ARA or bifidobacteria with the main milk powder in a dry mixer.

[0158] 14) Powder screening: Use a vibrating screen to make the particle size of the milk powder uniform and discard the powder residue.

[0159] 15) Powder output: Collect the powder in a sterilized powder box and transport it from the powder output room to the powder loading room.

[0160] 16) Powdering: Pour the milk powder into the powder storage tank on the large and small packaging machines according to the packaging requirements.

[0161] 17) Packaging: 400g automatic packaging machine nitrogen filling packaging. The oxygen content during nitrogen filling is less than 1%. 900g iron cans automatically filled with nitrogen packaging oxygen content is less than 5%.

[0162] 18) Packing: Put the packaged sachets into cartons and add the powder spoon, then seal with a carton sealing machine.

[0163] 19) Finished product inspection: Sampling inspection is carried out on the packaged products according to the inspection plan.

[0164] 20) Storage: Products that have passed the inspection shall be stored in warehouses at room temperature with humidity ≤ 65%.

[0165] Example 2

[0166] The present embodiment provides a powdered formula food for infants and children, wherein the total protein content of the powdered formula food is 10.5 g / 100 g powder, the fat content is 27 g / 100 g powder, the carbohydrate content is 54.6 g / 100 g powder, the DHA is 100 mg / 100 g powder, the ARA is 120 mg / 100 g powder, and the LNnt is 195 mg / 100 g powder, and the ratio of DHA:ARA:LNnt is 100:120:195.

[0167] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0168] 1000 parts of raw cow's milk, 360 parts of desalted whey powder (D90), 230 parts of edible vegetable blending oil, 170 parts of lactose, 30 parts of galacto-oligosaccharide, 25 parts of α-lactalbumin powder, 20 parts of casein, 8 parts of oligofructose, 5 parts of whey protein powder (rich in milk fat globule membrane), 4 parts of phospholipids, and 24 parts of compound nutrients, wherein the compound nutrients include about 4 parts of compound vitamin nutrition package, about 2 parts of choline chloride nutrition package, about 12 parts of mineral 2 nutrition package, about 1 part of mineral 1 nutrition package, about 2 parts of magnesium chloride nutrition package and about 3 parts of potassium chloride nutrition package, and the base materials of each nutrition package are lactose, 4 parts of lactose-N-neotetraose (LNnT), 13 parts of DHA, 15 parts of ARA, about 1 part of lactoferrin, 0.2 parts of bifidobacteria, and about 0.7 parts of nucleotides.

[0169] The specific preparation process of the infant and children's formula milk powder in this embodiment is consistent with that in Example 1.

[0170] Example 3

[0171] The present embodiment provides a powdered formula food for infants and children, wherein the total protein content of the powdered formula food is 10.5 g / 100 g powder, the fat content is 27 g / 100 g powder, the carbohydrate content is 52.2 g / 100 g powder, the DHA content is 100 mg / 100 g powder, the ARA content is 130 mg / 100 g powder, and the 6'-SL content is 300 mg / 100 g powder, and the ratio of DHA:ARA:6'-SL is 100:130:300.

[0172] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0173] 1500 parts of raw cow's milk, 490 parts of desalted whey powder (D90), 200 parts of edible vegetable blending oil, 20 parts of lactose, 30 parts of galacto-oligosaccharides, 15 parts of fructo-oligosaccharides, 5 parts of whey protein powder (rich in milk fat globule membrane), 4 parts of phospholipids, 24 parts of compound nutrients, wherein the compound nutrients include about 4 parts of compound vitamin nutrition package, about 2 parts of choline chloride nutrition package, about 12 parts of mineral 2 nutrition package, about 1 part of mineral 1 nutrition package, about 2 parts of magnesium chloride nutrition package and about 3 parts of potassium chloride nutrition package, and the base materials of each nutrition package are lactose, 3 parts of 6'-SL, 10 parts of DHA, 13 parts of ARA, about 2 parts of lactoferrin, 0.2 parts of bifidobacteria and about 0.4 parts of nucleotides.

[0174] The specific preparation process of the infant and children's formula milk powder in this embodiment is consistent with that in Example 1.

[0175] Example 4

[0176] The present embodiment provides a powdered formula food for infants and children, wherein the total protein content of the powdered formula food is 10.5 g / 100 g powder, the fat content is 27 g / 100 g powder, the carbohydrate content is 53.2 g / 100 g powder, the DHA content is 50 mg / 100 g powder, the ARA content is 60 mg / 100 g powder, and the LNnt content is 90 mg / 100 g powder, and the ratio of DHA:ARA:LNnt is 50:50:90.

[0177] 1400 parts of raw cow's milk, 500 parts of desalted whey powder (D90), 200 parts of edible vegetable blending oil, 37 parts of lactose, 30 parts of galacto-oligosaccharides, 15 parts of fructo-oligosaccharides, 5 parts of whey protein powder (rich in milk fat globule membrane), 4 parts of phospholipids, 24 parts of compound nutrients, wherein the compound nutrients include about 4 parts of compound vitamin nutrition package, about 2 parts of choline chloride nutrition package, about 12 parts of mineral 2 nutrition package, about 1 part of mineral 1 nutrition package, about 2 parts of magnesium chloride nutrition package and about 3 parts of potassium chloride nutrition package, and the base materials of each nutrition package are lactose, 1 part of lactose-N-neotetraose (LNnT), 4 parts of DHA, 4 parts of ARA, 0.2 parts of bifidobacteria and about 0.4 parts of nucleotides.

[0178] The specific preparation process of the infant and children's formula food of this embodiment is consistent with that of embodiment 1.

[0179] Experimental study on the efficacy of nutritional composition in improving individual social ability

[0180] 1. Bee species and grouping

[0181] One-day-old Italian honey bees (Apis mellifera) were used, and the intervention methods of different experimental groups were shown in Table 1 based on the diet of feed honey bees.

[0182] Table 1

[0183]

[0184] 2. Basic honey bee training

[0185] Preparation of diet for the CV group: Weigh 500 g of sucrose and 10 g of casein hydrolysate, dilute to 1 L with ultrapure water, stir to dissolve, filter and sterilize with a 0.22 μm filter membrane to obtain the 50% (w / v) sucrose solution containing 1% (w / v) casein hydrolysate required for the experiment.

[0186] Diet of treatment groups: The free-feeding group was given the treatment reagent on the basis of the CV diet; the single-fed group was given a daily diet of 40ul sugar water per bee, and the reagent was concentrated to 5ul sterile sugar water and gavage at one time.

[0187] Select honeycombs of appropriate age from the apiary, quickly transport them back to the laboratory, and place them in an incubator at 35°C and 60-80% humidity. Observe the status of the fledged bees every day from the second day (if they have not fledged, continue to culture), gently remove the fledged bees with tweezers and pack them into disposable transparent culture cups, 30 per cup, and pack enough cups according to the experimental needs.

[0188] The fledged bees were taken directly from the apiary, and the intestines were extracted. After adding 100ul PBS to each intestine and grinding, 50% glycerol was added in a 1:1 ratio and stored at -80°C.

[0189] Take a sterile 2mL centrifuge tube, add 990μL sterile PBS, add 10μL worker bee intestinal fluid, mix well, and finally use 50% (w / v) sterile sucrose solution to make up to 2mL mark, shake and mix well. Feed each cup of newly emerged bees with 1 tube of the above mixed solution and continue to culture in a constant temperature incubator for 24h.

[0190] After the colonization of intestinal fluid was completed, treatment feeding began. The CV group was fed with the CV diet, and the treatment group was fed with the treatment diet. Treatment feeding continued for 7 days. During this period, the growth status of the bees was observed daily and the diet was changed in time to ensure that the diet was sufficient. The culture conditions were: dark, 35℃, 60%-80% humidity.

[0191] Note: If the animal is gavage-fed individually, the diet placed in the feeding cup is CV diet, and only different treatment reagents are added to the gavage-fed diet.

[0192] 3. Experimental testing

[0193] Social behavior testing:

[0194] (1) Preparation of the behavioral observation room: Turn on the air conditioner and the exhaust fan of the test bench 1-2 hours before the experiment to keep the temperature of the observation room (26°C) constant and to ensure that there is no odor in the test bench.

[0195] (2) Place the experimental bees in groups of three in a transparent, breathable open field that has been prepared in advance.

[0196] (3) The open field was acclimated on the experimental table for 15 minutes, and the open field was filmed from above for 45 minutes.

[0197] (4) The above video was analyzed using the Etho Vision XT 17 animal behavior analysis system to obtain the social behavior ability data of honey bees.

[0198] 4. Experimental Results

[0199] The present invention analyzes the effect of DHA and ARA in a ratio of 1:1 on individual social behavior. Figures 1 to 6 The results showed that in terms of individual social behavior, compared with the conventional diet, the DHA and ARA in a ratio of 1:1 significantly improved the approach frequency, cumulative approach time, physical contact frequency, cumulative physical contact time, relative movement frequency, and cumulative relative movement time. This shows that the addition of DHA and ARA combination will enhance individual social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that the DHA and ARA combination has an active role in promoting cognitive development.

[0200] The present invention also analyzes the effects of different ratios of DHA and ARA on social behavior. The results are as follows: Figures 7 to 12As shown, bees fed a diet with a 1:1 ratio of DHA and ARA showed a significant trend in the frequency of physical contact, cumulative physical contact time, relative movement frequency, cumulative relative movement time, and cumulative approach time in the social behavior experiment compared with other groups. Bees fed a diet with a 1:1.5 and 1:2 ratio of DHA and ARA showed no significant trend in the detection of social behavior experimental indicators. Therefore, a DHA:ARA ratio of 1:1 was used in subsequent experiments for further verification.

[0201] The present invention also analyzed the effects of sialic acid HMO (i.e. 6-SL) and neutral sialic acid HMO (i.e. LNnT) on individual social behavior. Figures 13 to 18 As shown, the HMO-added groups, especially the 6-SL group, showed a significant trend in approach frequency, physical contact frequency, relative movement frequency, and cumulative approach time in the social behavior experiment compared with other groups. This shows that adding HMO, especially sialic acid HMO, will enhance individual social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that HMO has an effect in promoting cognitive development.

[0202] The present invention also analyzes the effect of DHA+ARA+HMO composition on social behavior. Figure 19-Figure 24 As shown in the results, compared with the DHA and ARA group with a ratio of 1:1, and the 6-SL and LNnT group, the DHA+ARA+6-SL and nDHA+ARA+LNnT groups showed obvious trends in the cumulative approach time, approach frequency, cumulative physical contact time, relative movement frequency, and cumulative relative movement time in the social behavior experiment. This shows that the DHA+ARA+6-SL / LNnT composition has a synergistic function in improving social willingness and social ability. Because social ability is one of the important indicators of cognitive development, it can be shown that the composition has a synergistic function in promoting cognitive development.

[0203] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A pediatric formula food, the pediatric formula food is an infant formula food, a toddler formula food or a children's formula food, the pediatric formula food has a total protein content of 10-30g / 100g, a fat content of 10-35g / 100g, a dietary fiber content of 0-6.5g / 100g, and a carbohydrate content of 45-60g / 100g; and the pediatric formula food contains DHA, ARA and human milk oligosaccharides 6-SL and / or LNnT, wherein: The mass ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is (70-210):(60-420):(10-400).

2. The pediatric formula food according to claim 1, wherein: The mass ratio of DHA to ARA is 0.2-5:1, preferably 0.3-3:1, and more preferably 0.5-2.5:

1.

3. The pediatric formula food according to claim 1 or 2, wherein: The mass ratio of DHA, ARA to human milk oligosaccharide 6-SL and / or LNnT is (70-210):(60-420):(40-400); Preferably, the mass ratio of DHA, ARA to human milk oligosaccharides 6-SL and / or LNnT is (70-210): (60-420): (80-400).

4. The pediatric formula food according to any one of claims 1 to 3, wherein: The food contains human milk oligosaccharide 6-SL and / or LNnT in an amount of 10-400 mg / 100 g of food dry matter; Preferably, the amount of human milk oligosaccharide 6-SL and / or LNnT contained in the food is 80-300 mg / 100 g of food dry matter.

5. The pediatric formula food according to any one of claims 1 to 4, wherein the linoleic acid content is 2700-4500 mg / 100 g of food dry matter, and the α-linolenic acid content is 270-450 mg / 100 g of food dry matter.

6. The pediatric formula food according to claim 1, wherein the raw materials thereof comprise:

7. A method for preparing the pediatric formula food according to any one of claims 1 to 6, the method comprising: Preparing raw materials for infant formula food, wherein the content of DHA, ARA and human milk oligosaccharide 6-SL and / or LNnT in the raw materials is adjusted; The raw materials are batched, homogenized, concentrated and sterilized, spray-dried and dry-mixed to prepare the pediatric formula food.

8. Use of the pediatric formula food according to any one of claims 1 to 6 in the preparation of a product that helps to enhance and / or improve the social behavior of an individual.

9. The use according to claim 8, wherein: The said enhancing and / or improving individual social behavior includes: enhancing individual social willingness and / or social ability; Preferably, the social ability includes social interaction ability and / or social adaptability.

10. The use according to claim 8 or 9, wherein: The individual is an infant, toddler or child.

Images